DE60037586D1 - Zellwachstumsinhibition - Google Patents
ZellwachstumsinhibitionInfo
- Publication number
- DE60037586D1 DE60037586D1 DE60037586T DE60037586T DE60037586D1 DE 60037586 D1 DE60037586 D1 DE 60037586D1 DE 60037586 T DE60037586 T DE 60037586T DE 60037586 T DE60037586 T DE 60037586T DE 60037586 D1 DE60037586 D1 DE 60037586D1
- Authority
- DE
- Germany
- Prior art keywords
- cell growth
- growth inhibition
- erbb
- cell
- arresting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
- C03C17/34—Surface treatment of glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions
- C03C17/3411—Surface treatment of glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions with at least two coatings of inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Geochemistry & Mineralogy (AREA)
- Materials Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ105799 | 1999-06-18 | ||
AUPQ1057A AUPQ105799A0 (en) | 1999-06-18 | 1999-06-18 | Cell growth inhibition |
PCT/AU2000/000671 WO2000078347A1 (en) | 1999-06-18 | 2000-06-16 | Cell growth inhibition |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60037586D1 true DE60037586D1 (de) | 2008-02-07 |
DE60037586T2 DE60037586T2 (de) | 2009-01-08 |
Family
ID=3815248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60037586T Expired - Lifetime DE60037586T2 (de) | 1999-06-18 | 2000-06-16 | Zellwachstumsinhibition |
Country Status (8)
Country | Link |
---|---|
US (2) | US9783456B1 (de) |
EP (3) | EP1187634B1 (de) |
JP (1) | JP4674020B2 (de) |
AT (1) | ATE381943T1 (de) |
AU (1) | AUPQ105799A0 (de) |
DE (1) | DE60037586T2 (de) |
ES (1) | ES2524006T3 (de) |
WO (1) | WO2000078347A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030007640A (ko) | 2000-05-19 | 2003-01-23 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
AU2008200654B2 (en) * | 2001-08-09 | 2010-04-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Inhibitors of HER3 activity |
EP1283053A1 (de) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitore der HER3 Aktivität |
JP4660094B2 (ja) | 2002-03-26 | 2011-03-30 | ゼンサン (シャンハイ) サイ−テク. リミテッド | 新生物を治療するためのErbB3に基づく方法および組成物 |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
PL1846030T3 (pl) | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
NZ590431A (en) | 2005-02-23 | 2012-08-31 | Genentech Inc | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
AU2007353412A1 (en) | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
AU2007324868B2 (en) | 2006-11-28 | 2014-03-20 | Daiichi Sankyo Europe Gmbh | Activated HER3 as a marker for predicting therapeutic efficacy |
DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
SI2171090T1 (sl) | 2007-06-08 | 2013-07-31 | Genentech, Inc. | Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
ES2433424T3 (es) | 2008-08-15 | 2013-12-11 | Merrimack Pharmaceuticals, Inc. | Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico |
EP2808339B1 (de) | 2008-11-28 | 2017-02-15 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin-Peptide und deren Verwendung |
EP2408817B1 (de) | 2009-03-20 | 2016-03-16 | F.Hoffmann-La Roche Ag | Bispezifische anti-her-antikörper |
WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
ES2655737T3 (es) | 2009-11-13 | 2018-02-21 | Daiichi Sankyo Europe Gmbh | Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3 |
CA2782571C (en) | 2009-12-22 | 2018-01-23 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
NZ602084A (en) | 2010-03-11 | 2014-07-25 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
DK2635604T3 (en) * | 2010-11-01 | 2017-02-27 | Symphogen As | PAN-HER-ANTIBODY COMPOSITION |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
EP3608340A1 (de) | 2011-11-23 | 2020-02-12 | Medlmmune, LLC | Her3-spezifische bindungsmoleküle und verwendungen davon |
CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
CA2865082A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
KR101933990B1 (ko) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | 인간화 panher 항체 조성물 |
CA2884051A1 (en) | 2012-10-08 | 2014-04-17 | Zensun (Shanghai) Science & Technology, Ltd. | Compositions and methods for treating heart failure in diabetic patients |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
US9180185B2 (en) * | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
EP3610905B1 (de) | 2013-05-22 | 2021-03-31 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Verlängerte freisetzung von neuregulin zur behandlung von herzinsuffizienz |
WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
EP3087394A2 (de) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
ES2166352T3 (es) * | 1989-08-04 | 2002-04-16 | Schering Ag | Dominio externo de c-erbb-2:gp75. |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
EP0871512A1 (de) | 1995-12-22 | 1998-10-21 | Localmed, Inc. | Lokale intravaskuläre abgabe von wachsfaktoren zur stimulierung von angiogenese |
US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
EP0896586B2 (de) * | 1996-03-27 | 2015-05-20 | Genentech, Inc. | ErbB3 ANTIKÖRPER |
IL127891A0 (en) | 1996-07-12 | 1999-10-28 | Genentech Inc | Chimeric heteromultimeter adhesins |
TR199901615T2 (en) * | 1996-10-18 | 1999-11-22 | Genentech, Inc. | Anti-ErbB2 antikorlar�. |
US5981201A (en) * | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
WO1998035036A1 (en) * | 1997-02-10 | 1998-08-13 | Genentech, Inc. | Heregulin variants |
SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
CA2409652A1 (en) | 2000-05-15 | 2001-11-22 | Giorgio Massimini | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
EP1283053A1 (de) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitore der HER3 Aktivität |
JP4660094B2 (ja) | 2002-03-26 | 2011-03-30 | ゼンサン (シャンハイ) サイ−テク. リミテッド | 新生物を治療するためのErbB3に基づく方法および組成物 |
RU2007135216A (ru) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | Биспецифические связывающие агенты для модулирования биологической активности |
DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
-
1999
- 1999-06-18 AU AUPQ1057A patent/AUPQ105799A0/en not_active Abandoned
-
2000
- 2000-06-16 ES ES07119791.7T patent/ES2524006T3/es not_active Expired - Lifetime
- 2000-06-16 AT AT00936539T patent/ATE381943T1/de not_active IP Right Cessation
- 2000-06-16 EP EP00936539A patent/EP1187634B1/de not_active Revoked
- 2000-06-16 WO PCT/AU2000/000671 patent/WO2000078347A1/en active IP Right Grant
- 2000-06-16 EP EP14175608.0A patent/EP2810653B1/de not_active Expired - Lifetime
- 2000-06-16 JP JP2001504409A patent/JP4674020B2/ja not_active Expired - Lifetime
- 2000-06-16 US US09/979,809 patent/US9783456B1/en not_active Expired - Fee Related
- 2000-06-16 DE DE60037586T patent/DE60037586T2/de not_active Expired - Lifetime
- 2000-06-16 EP EP07119791.7A patent/EP1889631B1/de not_active Revoked
-
2015
- 2015-11-24 US US14/951,290 patent/US20160152727A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160152727A1 (en) | 2016-06-02 |
EP1187634A1 (de) | 2002-03-20 |
AUPQ105799A0 (en) | 1999-07-08 |
EP1889631A1 (de) | 2008-02-20 |
EP1187634B1 (de) | 2007-12-26 |
DE60037586T2 (de) | 2009-01-08 |
WO2000078347A1 (en) | 2000-12-28 |
EP1187634A4 (de) | 2005-06-15 |
EP2810653A1 (de) | 2014-12-10 |
JP4674020B2 (ja) | 2011-04-20 |
ES2524006T3 (es) | 2014-12-03 |
EP1889631B1 (de) | 2014-09-03 |
EP2810653B1 (de) | 2020-01-08 |
US9783456B1 (en) | 2017-10-10 |
ATE381943T1 (de) | 2008-01-15 |
JP2003502386A (ja) | 2003-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60037586D1 (de) | Zellwachstumsinhibition | |
DZ3004A1 (fr) | Omega-carboxyaryl diphényl urées substitués comme inhibiteurs de raf kinase. | |
NO20015417L (no) | Behandling av autoimmune sykdommer med antagonister som binder til B-celleoverflatemarkörer | |
ZA200107409B (en) | Fuel composition. | |
MA26819A1 (fr) | Pteridinones servant d' inhibiteurs de kinases. | |
BR0106649B1 (pt) | composição fertilizante contendo enxofre. | |
TR199900853A3 (tr) | Sübstitüe edilmis trisiklik bilesikler. | |
MXPA03001777A (es) | Derivados de quinazolina como antagonistas adrenergicos alfa-1. | |
ZA200110413B (en) | Crystalline 1-methylcarbapenem compounds. | |
ZA200006463B (en) | Composition for keeping away vermin. | |
AU2001276425A1 (en) | Machine for planting stakes, poles or the like | |
NO20023172D0 (no) | 10, 11-difluormetylendioksycamptothecin-forbindelser med topoisomerase I inhibering | |
ZA200201789B (en) | Substituted pyrrolidin-2,3,4-trion-3-oxime drivatives useful as NMDA-receptor antagonists. | |
IT1309591B1 (it) | Composizioni a rilascio controllato di betaistina. | |
WO2001041709A3 (en) | Methods for treating cell death diseases and inflammation | |
EG23255A (en) | Floating hydrocarbon treating plant. | |
HK1044478A1 (en) | Resorcinol composition. | |
ZA200002546B (en) | Sorbate-preserved compositions, method for the manufacture thereof and their use. | |
ES1043300Y (es) | Taladro automatico. | |
ITPD20020134A0 (it) | Cassonetto ribaltabile, particolarmente per veicoli speciali multifunzione o simili. | |
NO20002573L (no) | Fremgangsmåte for å bevirke ventilasjon, samt ventilasjonsanlegg | |
ZA200201714B (en) | Novel compound F-15078. | |
FR2816280B3 (fr) | Marqueur pour chaine, en particulier pour chaine d'ancre | |
DK199900455U3 (da) | Ventilationsventil til etablering af ventilation, samt anvendelse heraf | |
ES1042349Y (es) | Cierre para arquetas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: ZENSUN (SHANGHAI) SCI-TECH, LTD., SHANGHAI, CN |
|
8363 | Opposition against the patent | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: JONES DAY RECHTSANWAELTE PATENTANWAELTE, 80538 MUE |